InvestorsObserver is giving Fate Therapeutics Inc (FATE) an Analyst Rating Rank of 20, meaning FATE is ranked higher by analysts than 20% of stocks. The average price target for FATE is $7.462 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating FATE a Buy today. Find out what this means to you and get the rest of the rankings on FATE!
You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers.
InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.
What's Happening With Fate Therapeutics Inc Stock Today?
Fate Therapeutics Inc (FATE) stock is trading at $2.09 as of 11:28 AM on Tuesday, Oct 24, an increase of $0.29, or 15.83% from the previous closing price of $1.80. The stock has traded between $1.80 and $2.10 so far today. Volume today is low. So far 469,845 shares have traded compared to average volume of 2,564,747 shares.
Click Here to get the full Stock Report for Fate Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
